Université Côte d'Azur, INSERM, C3M, 06204 Nice, France.
Pôle Technologique du CRCT - Plateau Bioinformatique INSERM-UMR 1037, Toulouse, France.
Cancer Cell. 2019 Sep 16;36(3):268-287.e10. doi: 10.1016/j.ccell.2019.07.008. Epub 2019 Aug 22.
GAPDH is emerging as a key player in T cell development and function. To investigate the role of GAPDH in T cells, we generated a transgenic mouse model overexpressing GAPDH in the T cell lineage. Aged mice developed a peripheral Tfh-like lymphoma that recapitulated key molecular, pathological, and immunophenotypic features of human angioimmunoblastic T cell lymphoma (AITL). GAPDH induced non-canonical NF-κB pathway activation in mouse T cells, which was strongly activated in human AITL. We developed a NIK inhibitor to reveal that targeting the NF-κB pathway prolonged AITL-bearing mouse survival alone and in combination with anti-PD-1. These findings suggest the therapeutic potential of targeting NF-κB signaling in AITL and provide a model for future AITL therapeutic investigations.
GAPDH 正在成为 T 细胞发育和功能的关键参与者。为了研究 GAPDH 在 T 细胞中的作用,我们生成了一种在 T 细胞谱系中过表达 GAPDH 的转基因小鼠模型。老年小鼠发生了外周 Tfh 样淋巴瘤,重现了人类血管免疫母细胞性 T 细胞淋巴瘤(AITL)的关键分子、病理和免疫表型特征。GAPDH 诱导了小鼠 T 细胞中非经典 NF-κB 途径的激活,该激活在人类 AITL 中强烈激活。我们开发了一种 NIK 抑制剂,以揭示靶向 NF-κB 途径可单独延长携带 AITL 的小鼠的存活时间,并且与抗 PD-1 联合使用时效果更好。这些发现表明在 AITL 中靶向 NF-κB 信号的治疗潜力,并为未来的 AITL 治疗研究提供了模型。